

Bulletin Officiel de la Propriété Industrielle (BOPI)

Brevets d'inventions

PUBLICATION

N° 03 BR / 2016

du 22 Décembre 2016

Organisation
Africaine de la
Propriété
Intellectuelle



SOMMAIRE

TITRE	PAGES
PREMIERE PARTIE : GENERALITES	2
Extrait de la norme ST3 de l'OMPI utilisée pour la représentation des pays et organisations internationales	3
Extrait de la norme ST9 de l'OMPI utilisée en matière de documentation des Brevets d'Invention et des Modèles d'Utilité	6
Codes utilisés en matière d'inscriptions dans les registres spéciaux des Brevets d'Invention et des Modèles d'Utilité	6
Clarification du règlement relatif à l'extension des droits suite à une nouvelle adhésion à l'Accord de Bangui	7
Adresses utiles	8
DEUXIEME PARTIE : BREVETS D'INVENTION	9
Repertoire numérique du N° 17422 au N° 17461	10
Repertoire suivant la C.I.B	31
Repertoire des noms	33

**PREMIERE PARTIE
GENERALITES**

Extrait de la norme ST.3 de l'OMPI

Code normalisé à deux lettres recommandé pour la représentation des pays ainsi que d'autres entités et des organisations internationales délivrant ou enregistrant des titres de propriété industrielle.

Afghanistan	AF	Cook, Îles	CK
Afrique du Sud	ZA	Corée (République de Corée)	KR
Albanie	AL	Corée (Rép. Populaire de Corée)	KP
Algérie	DZ	Costa Rica	CR
Allemagne	DE	Côte d'Ivoire*	CI
Andorre	AD	Croatie	HR
Angola	AO	Cuba	CU
Anguilla	AI	Danemark	DK
Antigua-et-Barbuda	AG	Djibouti	DJ
Antilles Néerlandaises	AN	Dominicaine, République	DO
Arabie Saoudite	SA	Dominique	DM
Argentine	AR	Egypte	EG
Arménie	AM	El Salvador	SV
Aruba	AW	Emirats Arabes Unis	AE
Australie	AU	Equateur	EC
Autriche	AT	Erythrée	ER
Azerbaïdjan	AZ	Espagne	ES
Bahamas	BS	Estonie	EE
Bahreïn	BH	Etats-Unis d'Amérique	US
Bangladesh	BD	Ethiopie	ET
Barbade	BB	Ex Rep. Yougoslavie de Macedoine	MK
Bélarus	BY	Falkland, Îles (Malvinas)	FK
Belgique	BE	Fédération de Russie	RU
Belize	BZ	Fidji	FJ
Bénin*	BJ	Féroé, Îles	FO
Bermudes	BM	Finlande	FI
Bhoutan	BT	France	FR
Bolivie	BO	Gabon*	GA
Bonaire, Saint-Eustache et Saba	BQ	Gambie	GM
Bosnie-Herzégovine	BA	Géorgie	GE
Botswana	BW	Géorgie du Sud et les Îles Sandwich du Sud	GS
Bouvet, Île	BV	Ghana	GH
Brésil	BR	Gibraltar	GI
Brunéi Darussalam	BN	Grèce	GR
Bulgarie	BG	Grenade	GD
Burkina Faso*	BF	Groenland	GL
Burundi	BI	Guatemala	GT
Caïmanes, Îles	KY	Guernesey	GG
Cambodge	KH	Guinée*	GN
Cameroun*	CM	Guinée-Bissau*	GW
Canada	CA	Guinée Equatoriale*	GQ
Cap-Vert	CV	Guyana	GY
Centrafricaine, République*	CF	Haïti	HT

Chili	CL	Honduras	HN
Chine	CN	Hong Kong	HK
Chypre	CY	Hongrie	HU
Colombie	CO	Île de Man	IM
Comores*	KM	Îles Vierges (Britanniques)	VG
Congo*	CG	Inde	IN
Congo(Rép.Démocratique)	CD	Indonésie	ID
Iran(République Islamique d')	IR	Norvège	NO
Iraq	IQ	Nouvelle-Zélande	NZ
Irlande	IE	Oman	OM
Islande	IS	Ouganda	UG
Israël	IL	Ouzbékistan	UZ
Italie	IT	Pakistan	PK
Jamaïque	JM	Palaos	PW
Japon	JP	Panama	PA
Jersey	JE	Papouasie-Nouvelle-Guinée	PG
Jordanie	JO	Paraguay	PY
Kazakhstan	KZ	Pays-Bas	NL
Kenya	KE	Pérou	PE
Kirghizistan	KG	Philippines	PH
Kiribati	KI	Pologne	PL
Koweït	KW	Portugal	PT
Laos	LA	Qatar	QA
Lesotho	LS	Région admin. Spéciale de Hong Kong (Rep. Populaire de Chine)	HK
Lettonie	LV	Roumanie	RO
Liban	LB	Royaume Uni (Grande Bretagne)	GB
Libéria	LR	Rwanda	RW
Libye	LY	Sahara Occidental	EH
Liechtenstein	LI	Sainte-Hélène	SH
Lituanie	LT	Saint-Kitts-et-Nevis	KN
Luxembourg	LU	Sainte-Lucie	LC
Macao	MO	Saint-Marin	SM
Macédoine	MK	Saint-Marin (Partie Néerlandaise)	SX
Madagascar	MG	Saint-Siège(Vatican)	VA
Malaisie	MY	Saint-Vincent-et-les Grenadines(a,b)	VC
Malawi	MW	Salomon, Îles	SB
Maldives	MV	Samoa	WS
Mali*	ML	Sao Tomé-et-Principe	ST
Malte	MT	Sénégal*	SN
Mariannes du Nord, Îles	MP	Serbie	RS
Maroc	MA	Seychelles	SC
Maurice	MU	Sierra Leone	SL
Mauritanie*	MR	Singapour	SG
Mexique	MX	Slovaquie	SK
Moldova	MD	Slovénie	SI
Monaco	MC	Somalie	SO

Mongolie	MN	Soudan	SD
Monténégro	ME	SriLanka	LK
Montserrat	MS	Suède	SE
Mozambique	MZ	Suisse	CH
Myanmar(Birmanie)	MM	Suriname	SR
Namibie	NA	Swaziland	SZ
Nauru	NR	Syrie	SY
Népal	NP	Tadjikistan	TJ
Nicaragua	NI	Taiwan,Province de Chine	TW
Niger*	NE	Tanzanie (Rép.-Unie)	TZ
Nigéria	NG	Tchad*	TD
Thaïlande	TH	Tchèque,République	CZ
Timor Oriental	TP	Ukraine	UA
Togo*	TG	Uruguay	UY
Tonga	TO	Vanuata	VU
Trinité-et-Tobago	TT	Venezuela	VE
Tunisie	TN	VietNam	VN
Turkménistan	TM	Yémen	YE
Turks et Caïques,Îles	TC	Yougoslavie	YU
Turquie	TR	Zambie	ZM
Tuvalu	TV	Zimbabwe	ZW

ORGANISATIONS INTERNATIONALES DELIVRANT OU ENREGISTRANT DES TITRES DE PROPRIETE INDUSTRIELLE

Bureau Benelux des marques et des dessins et modèles industriels	BX
Office Communautaire des variétés végétales (Communauté Européenne (OCVV))	QZ
Office de l'harmonisation dans le marché intérieur (Marque, dessins et modèles)	EM
Office des Brevets du conseil de Coopération des Etats du Golf (CCG)	GC
Office Européen des Brevets (OEB)	EP
Organisation Mondiale de la Propriété Intellectuelle (OMPI)	WO
Bureau International de l'OMPI	IB
Organisation Africaine de la Propriété Intellectuelle (OAPI)	OA
Organisation Eurasienne des Brevets (OEAB)	EA
Organisation Régionale Africaine de la Propriété Industrielle (ARIPO)	AP

*Etats membres de l'OAPI

**CODES UTILISES EN MATIERE DE DOCUMENTATION DES
BREVETS D'INVENTION ET DES MODELES D'UTILITE**

- (11) Numéro de publication.
- (12) Désignation du type de document.
- (19) Identification de l'office qui publie le document.
- (21) Numéro d'enregistrement ou de dépôt.
- (22) Date de dépôt.
- (24) Date de délivrance.
- (30) Pays dans lequel (lesquels) la(les) demande(s) de priorité a (ont) été déposée(s).
Date(s) de dépôt de la (des) demande(s) de priorité.

(le cas échéant)

Numéro(s) attribué(s) à la (aux) demande(s) de priorité.

- (51) Classification internationale des brevets(CIB).
- (54) Titre de l'invention.
- (57) Abrégé.
- (60) Références à d'autres documents apparentés (le cas échéant).
- (71) Nom(s) du ou des demandeur(s).
- (72) Nom de l'inventeur (le cas échéant) suivi éventuellement du nom de la société d'appartenance.
- (73) Nom(s) du ou des titulaire(s) le cas échéant.
(Ce code n'apparaît que sur la première page du brevet délivré)
- (74) Nom du mandataire en territoire OAPI (le cas échéant).

**CODES UTILISES EN MATIERE D'INSCRIPTIONS
DANS LE REGISTRE SPECIAL DES BREVETS D'INVENTION ET DES
MODELES D'UTILITE**

- (1) Numéro de délivrance
- (2) Numéro de dépôt
- (3) Numéro et date de la demande d'inscription
- (4) Nature de l'inscription
- (5) Numéro et date de l'inscription
- (10) Cédant
- (11) Cessionnaire
- (12) Apporteur
- (13) Bénéficiaire
- (14) Dénomination avant
- (15) Dénomination après
- (16) Concédant
- (17) Titulaire
- (18) Ancienne adresse
- (19) Nouvelle adresse
- (20) Constituant du nantissement
- (21) Créancier nanti

**CLARIFICATION DU REGLEMENT RELATIF A L'EXTENSION DES DROITS
SUITE A UNE NOUVELLE ADHESION A L'ACCORD DE BANGUI****RESOLUTION N°47/32****LE CONSEIL D'ADMINISTRATION
DE L'ORGANISATION AFRICAINE DE LAPROPRIETE INTELLECTUELLE**

- Vu L'accord portant révision de l'accord de Bangui du 02 Mars 1977 instituant une Organisation Africaine de la Propriété Intellectuelle et ses annexes ;
- Vu Les dispositions des articles 18 et 19 dudit Accord relatives Aux attributions et pouvoirs du Conseil d'Administration ;

ADOPTE la clarification du règlement du 04 décembre 1988 relatif à l'extension des droits suite à une nouvelle adhésion à l'Accord de Bangui ci-après :

Article 1er :

Le Règlement du 04 décembre 1988 relatif à l'extension des droits suite à une nouvelle adhésion à l'Accord de Bangui est réaménagé ainsi qu'il suit :

«Article 5 (nouveau) :

Les titulaires des titres en vigueur à l'Organisation avant la production des effets de l'adhésion d'un Etat à l'accord de Bangui ou ceux dont la demande a été déposée avant cette date et qui

voudront étendre la protection dans ces Etats doivent formuler une demande d'extension à cet effet auprès de l'Organisation suivant les modalités fixées aux articles 6 à 18 ci-dessous.
Le renouvellement de la protection des titres qui n'ont pas fait l'objet d'extension avant l'échéance dudit renouvellement entraîne une extension automatique des effets de la protection à l'ensemble du territoire OAPI».

Le reste sans changement.

Article 2 :

La présente clarification, qui entre en vigueur à compter du 1^{er} janvier 2008, s'applique aussi aux demandes d'extension en instance et sera publiée au Bulletin Officiel de l'Organisation.

Fait à Bangui le 17 décembre 2007

STRUCTURES NATIONALES DE LIAISON (SNL)

BENIN-Cotonou

Agence Nationale de la Propriété Industrielle (ANAPI)

Tel.: (229) 21 31 02 40
Fax.: (229) 21 30 30 24
01 B.P. 363 Cotonou 01

BURKINA FASO-Ouagadougou

Direction Nationale de la Propriété Industrielle (DNPI)

(Ministère de l'Industrie, du Commerce et de l'Artisanat)
Tél. : (226) 50 30 09 41
Fax : (226) 50 33 05 63
01 B.P. 258 Ouagadougou

CAMEROUN-Yaoundé

Direction du Développement Technologique et de la Propriété Industrielle

(Ministère des Mines, de l'Industrie et du Développement Technologique)
Tel. : (237) 22 20 37 78
Fax: (237) 22 20 37 38
B.P. 1652 Yaoundé

CENTRAFRIQUE-Bangui

Direction de la Propriété Industrielle (Ministère du Commerce et de l'Industrie)

Tél. : (236) 21 61 17 44
Fax : (236) 21 61 76 53
Avenue B. BOGANDA
B.P. 1988 Bangui

COMORES-Moroni

Office comorien de la propriété intellectuelle

Tél. : 269 333 53 60
Fax : 269 775 00 03
B.P. 41 Moroni

CONGO-Brazzaville

Antenne Nationale de la Propriété Industrielle (ANPI)

(Ministère du Développement Industriel et de la Promotion du Secteur Privé)
Tél. : (242) 581 56 57
Fax : (242) 581 54 80
B.P. : 72 Brazzaville

COTE D'IVOIRE-Abidjan

Office Ivoirien de la Propriété Industrielle (OIPD)

Tel. : (225) 20 33 53 43/44
Fax: (225) 20 33 53 45
01 B.P. 2337 Abidjan

GABON-Libreville

Centre de la Propriété Industrielle du Gabon (CEPIG)

(Ministère du Commerce et du Développement Industriel, Chargé du NEPAD)
Tel. : (241) 01 74 59 24
Fax. : (241) 01 76 30 55
B.P. : 1025 Libreville

GUINEE-Conakry

Service National de la Propriété Industrielle

(Ministère de l'Industrie, des Petites et Moyennes Entreprises)
Tel. : (224) 30 41 17 20/60 58 53 61
Fax: (224) 41 25 42/41 39 90
B.P. 468 Conakry

GUINEE BISSAU-Bissau

Direction Générale de la Propriété Industrielle

(Ministère du Commerce, de l'Industrie et de la Promotion des Produits locaux)
Tél : (245) 322 22 75
Fax : (245) 322 37 65
B.P. : 269 Bissau

GUINEE EQUATORIALE-Malabo

Direction de la Propriété Intellectuelle

(Conseil de la Recherche Scientifique et Technique - CICTE)
Tel. : (240) 222 09 24 84
Fax : (240) 333 09 33 13
B.P. : 528 Malabo

MALI-Bamako

Centre Malien de la Propriété Industrielle (CEMAPI)

Tel. : (223) 20 29 90 90
Fax: (223) 20 29 90 91
B.P. : 278 Bamako

MAURITANIE-Nouakchott

Service de la Technologie et de la Propriété Industrielle

(Ministère du Commerce, de l'Industrie, de l'Artisanat et du Tourisme)
Tel. : (222) 525 72 66
Fax: (222) 525 69 37
B.P. : 387 Nouakchott

NIGER-Niamey

Direction de l'Innovation et de la Propriété Intellectuelle

(Ministère des Mines et du Développement Industriel)
Tél. : (227) 20 73 58 25
Fax : (227) 20 73 21 50
B.P. : 480 Niamey

SENEGAL-Dakar

Agence Sénégalaise pour la Propriété Industrielle et l'Innovation Technologique (ASPIT)

Tel. : (221) 33 869 47 70
Fax: (221) 33 827 30 14
B.P. : 4037 Dakar

TCHAD-N'djamena

Division de la Propriété Industrielle et de la Technologie (Ministère du Commerce et de l'Industrie)

Tel. : (235) 22 52 08 67
Fax: (235) 22 52 21 79
B.P. : 424 N'Djamena

TOGO-Lomé

Institut National de la Propriété Industrielle et de la Technologie (INPIT)

Tel. : (228) 222 10 08
Fax : (228) 222 44 70
B.P. : 2339 Lomé



OAPI

B.P. 887 Yaoundé-Cameroun Tél : (237) 22 20 57 00

E-mail : oapi@oapi.int

Fax : (237) 22 20 57 27

www.oapi.int

**DEUXIEME PARTIE
BREVETS D'INVENTION**

A
REPERTOIRE NUMERIQUE
du N° 17422 au 17461

(11) **17422**

(51) A61P 31/00

(21) 1201200456

(22) 05.12.2012

(54) Pommade antimycosique et procédé.

(72) Dr NYEMBA Anne-Marie;

Dr NGONO MBALLA Rose;

Dr MBEMKUM FONKI Tobias;

Dr MBITA MESSI Hubert;

Dr KAMDEM Lucien;

Dr AGBOR Gabriel;

Dr NGANGOUE Joseph;

Dr TCHINDA TIABOU Alembert;

Dr NNANGA NGA Emmanuel;

Dr KALTJOB Stella;

Dr TSABANG Nolé;

Mr ATANGANA NDONGO;

Mr TARKANG AREY Protus;

Mr KINGA Joseph YENIKA;

Prof. ESSAME OYONO;

Dr BIYITI née AKEM ADA Lucie);

Dr TAMZE Victorine;

Dr TIH EWOLA Anastasie;

Dr MBI Christina;

Dr BOUM Bernard.

(73) INSTITUT DE RECHERCHES MEDICALES ET D'ETUDES DES PLANTES MEDICINALES (IMPM) (CM)

(74) AFRIC'INTEL CONSULTING, B.P. 8451, YAOUNDE (CM).

(57) La présente invention porte sur une composition chimique à usage dermatologique et aux propriétés antibactériennes obtenue à base d'une plante couramment appelée happy gardening ou Adam's apple et dont le nom scientifique est *Taberneamontana crassa*. Elle se présente sous la forme d'une pommade obtenue par le mélange du filtrat obtenu de l'extrait éthanolique total de *Taberneamontana* à d'autres excipients notamment e benzoate de sodium, la vaseline blanche, la glycérine pure, la lanoline et

l'eau purifiée. La pommade obtenue est efficace dans le traitement des infections dermatologiques notamment infections bactériennes de la peau et des muqueuses, pyodermies, furoncles et abcès après incision, folliculite de la barbe, ecthyma, impétigo, onyxis, pityriasis streptogènes, eczémas et dermatoses surinfectées, ulcère de la jambe, couverture antibactérienne locale dans les brûlures, brûlure par eau bouillante, plaies superficielles postopératoires et traumatiques.

[Consulter le mémoire](#)

(11) **17423**

(51) C02F 1/46 (06.01)

(21) 1201500193 - PCT/EP13/003523

(22) 21.11.2013

(30) US n° 13/683,212 du 21/11/2012

(54) Apparatus and method for water treatment mainly by substitution using a dynamic electric field.

(72) AANENSEN, Ove T.;

AANENSEN, Ove T.;

VALAND, Dag Arild.

(73) AANENSEN, Ove T. (NO);

VALAND, Dag Arild (DE)

(74) Cabinet ISIS CONSEILS (SCP), 29, Boulevard du Lamido de Rey Bouba - Mballa II, B.P. 15424, YAOUNDE (CM).

(57) An apparatus, method, process, and system for the treatment of a water stream are provided. Such apparatus, method, process, and system characterized by applying a voltage to a pair of electrodes to generate an electric field with such electric field applied across a water stream passing there between the pair of electrodes. At least one of the pair of electrodes comprises a metal, and one or more of a plurality of positively charged ions in the water stream are substituted with one or more positively charged ions of the metal. Additionally, one or more of a plurality of negatively charged ions may react with the one or more positively charge ions of the metal to form an ionic compound. One or more of any remaining of the plurality of positively charged ions may reaction with another one or more of the plurality of negatively charged ions.




FIG. 1

[Consulter le mémoire](#)

(11) **17424**

(51) H04B 1/00 (06.01)

(21) 1201500219 - PCT/US13/074823

(22) 12.12.2013

(30) US n° 13/712,607 du 12/12/2012

(54) RFIC configuration for reduced antenna trace loss.

(72) LIN, I-Hsiang;

XIONG, Zhijie;

KRISHNAMOORTHY, Seshagiri;

KO, Jin-Su;

AKULA, Prashanth;

ZHAO, Liang;

WANG, Kevin Hsi Huai;

ZHAO, Desong.

(73) QUALCOMM INCORPORATED (US)

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) An RFIC configuration for reduced antenna trace loss is disclosed. In an exemplary embodiment, an apparatus includes a primary RFIC and a secondary RFIC that is configured to receive analog signals from at least two antennas. The secondary RFIC is configured to process selected analog signals received from at least one antenna to generate an analog output that is input to the primary RFIC.




FIG. 4

[Consulter le mémoire](#)

(11) **17425**

(51) H02H 9/02 (06.01)

(21) 1201500220 - PCT/DZ13/000006

(22) 07.11.2013

(30) DZ n° 120838 du 09/12/2012

(54) Interface having earth fault current.

(72) Mekimah, Djamel.

(73) Mekimah, Djamel (DZ)

(74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, Blvd. du 20 Mai, Immeuble Centre Commercial de l'Hôtel Hilton, 2è Etage, Porte 208A, P.O. Box 8211, YAOUNDE (CM).

(57) The invention concerns an interface for cutting off the power supply for any fault current I_d s 300 milliamperes such that : $I_d > I_{PE} + kxI_h$. where IPE represents the current returning to the power source via the protective conductor connecting the exposed conductive parts to earth and $I_h (< 10$ or 30 milliamperes) represents the current returning to the power source by means other than via the protective conductor or via an active conductor. Current I_h is therefore likely to travel through a person. In this way, the interface protects people and property against ground insulation faults and against certain direct contacts independently of the earth of the exposed conductive parts and of external conditions. It also protects people in the event of a failure in the protection of an area using the same earth in case of a fault.




FIG.1

[Consulter le mémoire](#)




FIG. 2

[Consulter le mémoire](#)

(11) **17426**

(51) H04W 48/08 (06.01)

(21) 1201500221 - PCTUS13/074413

(22) 11.12.2013

(30) US n° 61/736,417 du 12/12/2012

US n° 61/798,861 du 15/03/2013

US n° 14/102,475 du 10/12/2013

(54) System and method for improved communication on a wireless network.

(72) JAFARIAN, Amin;

MERLIN, Simone.

(73) QUALCOMM INCORPORATED (US)

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) Systems and methods for wireless communication are disclosed. In one aspect an access point includes a processor configured to generate a message identifying a time period during which the apparatus is to communicate data with one or more wireless devices, the message further including an indicator indicating a wireless communication flow direction during the time period. The access point further includes a transmitter configured to transmit the generated message.

(11) **17427**

(51) E02F 7/00 (06.01)

(21) 1201500222 - PCT/AU13/001478

(22) 17.12.2013

(30) AU n° 2012905537 du 17/12/2012

AU n° 2013204655 du 12/04/2013

(54) Mobile ore slurring apparatus.

(72) REYNOLDS Christopher James;

SZETO Oliver;

CHASE Timothy Peter;

VANDENBERG Albert;

STANBOROUGH Adam James;


ARAUJO Victor;

SWART Gavin Martin.

(73) Bemax Resources Limited (AU)

(74) Cabinet ÉKÉMÉ LYSAGHT SARL, B.P. 6370, YAOUNDE (CM).

(57) A mobile ore slurring apparatus comprising: a feeding unit; a processing unit; and a pumping apparatus, wherein the processing unit is separated into a slurry tank section and a water tank section, such that ore may be passed from the feeding unit to the slurry tank where it is contacted with water from an overflow of the water tank to produce a slurry stream, the slurry stream is then transferred from the processing unit by way of the pumping apparatus.



[Consulter le mémoire](#)

(11) **17428**

(51) G01C 11/06 (06.01)

(21) 1201500223 - PCTUS13/075354

(22) 16.12.2013

(30) US n° 61/737,499 du 14/12/2012


(54) Apparatus and method for three dimensional surface measurement.

(72) DUMONT, Arnaud;
JALLON, Fred;
RAYMOND, Patrick;
KESTNER, Jason;
PARIMI, Madhav.

(73) BP CORPORATION NORTH AMERICA, INC. (US)

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) A system and method for three-dimensional measurement of surfaces. In one embodiment, a measurement system includes a laser projector, a first camera, and a processor. The laser projector is configured to emit a laser projection onto a surface for laser triangulation. The first camera is configured to provide images of the surface, and is disposed at an oblique angle with respect to the laser projector. The processor is configured to apply photogrammetric processing to the images, to compute calibrations for laser triangulation based on a result of the photogrammetric processing, and to compute, based on the calibrations, coordinates of points of the surface illuminated by the laser projection via laser triangulation.



[Consulter le mémoire](#)

(11) **17429**

(51) E21B 7/08 (06.01)

(21) 1201500228 - PCT/US13/074904

(22) 13.12.2013

(30) US n° 61/736,982 du 13/12/2012
US n° 14/104,639 du 12/12/2013

(54) Coring bit to whipstock systems and methods.

(72) CAMPBELL, John;
SWADI, Shantanu N.;
DEWEY, Charles;
UTTER, Robert;
DESAI, Praful C.

(73) PRAD Research and Development Limited (VG)

(74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, Blvd. du 20 Mai, Immeuble Centre Commercial de l'Hôtel Hilton, 2è Etage, Porte 208A, P.O. Box 8211, YAOUNDE (CM).

(57) A coring system and method enable a single-trip operation for setting a deflector assembly, deploying a coring assembly and obtaining a core sample from a borehole drilled in a wellbore. The coring assembly has a barrel with a bore for collecting the core sample and has a coring bit coupled to an end portion of the barrel. The deflector system is arranged to deflect the coring bit into a side wall of the wellbore to drill the borehole therein. The deflector system includes a deflector and a collar. The collar, coupled to the deflector, restricts upward movement of the coring assembly relative to the deflector assembly. The

collar may also be used as a retrieval device to engage the coring assembly and permit removal of the coring assembly and the deflector assembly as well as the core sample after the core sample has been obtained.




Fig. 7

[Consulter le mémoire](#)

(11) **17430**

(51) B42D 15/10 (06.01)

(21) 1201500230 - PCT/NL13/050872

(22) 04.12.2013

(30) NL n° 2010045 du 21/12/2012

(54) Identity document comprising a ghost image based on a two-dimensional image.


(72) VAN DEN BERG Jan.

(73) Morpho B.V. (NL)

(74) Cabinet ÉKÉMÉ LYSAGHT SARL, B.P. 6370, YAOUNDE (CM).

(57) An identity document includes in a single plane a two-dimensional image and under optical means a ghost image for verifying the authenticity of the two-dimensional image. The ghost image is a stereo image and the stereo image is based on the two-dimensional image. The stereo image includes at least two images of the person on the identity card wherein at least one of the two images is a calculated image. The stereo image may further include a floating image, the floating image being arranged to be perceived to float over the ghost image.

Fig 1



[Consulter le mémoire](#)

(11) **17431**

(51) B62K 5/05 (06.01)

(21) 1201500237 - PCT/JP13/084149

(22) 19.12.2013

(30) JP n° 2012-277219 du 19/12/2012

JP n° 2012-277220 du 19/12/2012

(54) Vehicle.


(72) TAKANO Kazuhisa.

(73) YAMAHA HATSUDOKI KABUSHIKI KAISHA (JP)

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) An object of the invention is to provide a vehicle including a body frame that can lean and two front wheels that can restrict the enlargement of a peripheral construction of a steering shaft that lies above the two front wheels while maintaining a function of a link mechanism. There is provided a vehicle 1 that includes a body frame that can lean and a right front wheel and a left front wheel and in which an upper cross portion 51 and a lower cross portion 52 of a link mechanism 5 each include a piece of part that is supported on side portions at a right end portion and a left end portion thereof and that is supported on a body frame at a middle portion thereof. The upper cross portion 51 and the lower cross portion 52 have different shapes. In the vehicle 1, regarding an upper right displacement X1 and an upper left displacement X2 that result when a rearward test force is exerted on an upper right bearing and an upper left bearing that support the upper cross portion 51 with the lower cross portion 52

removed and a lower right displacement X3 and a lower left displacement X4 that result when a rearward test force is exerted on a lower right bearing and a lower left bearing that support the lower cross portion 52 with the upper cross portion 51 removed, X1 and X2 are equal, X3 and X4 are equal, X1 and X3 are different, and X2 and X4 are different.



[Consulter le mémoire](#)

(11) **17432**

(51) B62K 5/08

(21) 1201500238 - PCT/JP13/084148

(22) 19.12.2013

(30) JP n° 2012-277219 du 19/12/2012

JP n° 2012-277220 du 19/12/2012

(54) Vehicle.


(72) TAKANO Kazuhisa (JP)

(73) YAMAHA HATSUDOKI KABUSHIKI KAISHA (JP)

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) An object of the invention is to provide a vehicle including a body frame that can lean and two front wheels that can restrict the enlargement of a peripheral construction of a steering shaft that lies above the two front wheels while maintaining a function of a link mechanism. There is provided a vehicle 1 that includes a body frame that can lean, as well as a right front wheel and a left front

wheel and in which an upper cross portion and a lower cross portion of a link mechanism 5 each includes a piece of part that is supported on side portions at a right end portion and a left end portion thereof and that is supported on a body frame at a middle portion thereof. The upper cross portion 51 and the lower cross portion 52 have different volumes. In the vehicle 1, upper displacements X1, X2 that result when a rearward test force is exerted on an upper right bearing and an upper left bearing that support the upper cross portion 51 with the lower cross portion 52 removed and lower displacements X3, X4 that result when a rearward test force is exerted on a lower right bearing and a lower left bearing that support the lower cross portion 52 with the upper cross portion 51 removed are equal.



[Consulter le mémoire](#)

(11) **17433**

(51) B62K 5/08 (06.01)

(21) 1201500239 - PCT/JP13/084146

(22) 19.12.2013

(30) JP n° 2012-277219 du 19/12/2012

JP n° 2012-277220 du 19/12/2012

JP n° 2013-138484 du 01/07/2013


(54) Vehicle.

(72) TAKANO Kazuhisa.

(73) YAMAHA HATSUDOKI KABUSHIKI KAISHA (JP)

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) An object of the invention is to provide a vehicle including a vehicle body frame that can lean and two front wheels that can enhance the degree of freedom in designing a link mechanism while maintaining the function of the link mechanism. There is provided a vehicle 1 that includes a vehicle body frame that can lean and a right front wheel and a left front wheel and in which an upper cross portion and a lower cross portion of a link mechanism 5 each include a piece of part that is supported on side portions at a right end portion and a left end portion thereof and that is supported on a vehicle body frame at a middle portion thereof. In the vehicle 1, an upper right displacement $X1$ and an upper left displacement $X2$ that result when a rearward test force is exerted individually on a lower right supporting portion and a lower left supporting portion that support the lower cross portion 52 with the lower cross portion 52 removed are larger than a lower right displacement $X3$ and a lower left displacement $X4$ that result when a force that is the same in magnitude and direction as the forces exerted on the lower right and left supporting portions is exerted individually on an upper right supporting portion and a upper left supporting portion that support the upper cross member 51 with the upper cross portion 51 removed.



[Consulter le mémoire](#)

(11) **17434**

(51) B62K 5/10 (06.01)

(21) 1201500245 - PCT/JP13/084341

(22) 20.12.2013

(30) JP n° 2012-278878 du 21/12/2012

JP n° 2012-278879 du 21/12/2012

JP n° 2013-138481 du 01/07/2013

(54) Vehicle.


(72) IIZUKA Toshio;

HIRAYAMA Yosuke.

(73) YAMAHA HATSUDOKI KABUSHIKI KAISHA (JP)

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) A vehicle is provided which can restrict the enlargement of the vehicle even though a vehicle component is mounted. There is provided a vehicle having a body frame 21, a left front wheel 31 and a right front wheel 32, a link mechanism 5 that can be deformed as a vehicle body leans, and vehicle components 81, 82, 221, 222 that are disposed directly ahead of the link mechanism 5 in relation to a front-and-rear direction of the vehicle, wherein the vehicle components 81, 82, 221, 222 are supported on the body frame 21 via penetrating portions 211a, 211b that extends to the front from the body frame 21 to penetrate the link mechanism 5.



[Consulter le mémoire](#)

(11) 17435

(51) F16L 15/00 (06.01)

(21) 1201500246 - PCT/EP13/076841


(22) 17.12.2013

(30) FR n° 1262580 du 21/12/2012

(54) Assembly for producing a galling-resistant threaded tubular connection.

(72) GARD Eric;
GOUIDER Mohamed;
PETIT Mikael.(73) VALLOUREC OIL AND GAS FRANCE
(FR);NIPPON STEEL & SUMITOMO METAL
CORPORATION (JP)(74) Cabinet CAZENAVE SARL, B.P. 500,
YAOUNDE (CM).

(57) The invention concerns an assembly for the production of a threaded connection, comprising a first and a second tubular component each with an axis of revolution (10) and each provided at one of their ends (1,2) with a threaded zone (3; 4) produced on the outer or inner peripheral surface of the component depending on whether the threaded end is male or female in type, said ends (1,2) being capable of cooperating by makeup and ending in a terminal surface (7, 8), at least one first contact surface being provided on one of the ends (1, 2) and at least one second contact surface being provided on the corresponding end (1, 2), such that the first and second contact surfaces come into contact during makeup of the ends (1, 2), characterized in that the first and second contact surfaces are respectively each coated with a first and a second dry thermoplastic film the matrices of which are constituted by one or more thermoplastic polymers, only one of the first and second dry thermoplastic films further comprising a liquid amorphous thermoplastic resin with a dynamic viscosity in the range 2000 to 40000 mPa.s at 25°C.

**Fig.1**[Consulter le mémoire](#)**(11) 17436**

(51) A61K 38/26 (06.01)

(21) 1201500247 - PCT/EP13/077310

(22) 19.12.2013

(30) EP n° 12306647.4 du 21/12/2012

(54) Functionalized exendin-4 derivatives.

(72) HAACK Torsten;
WAGNER Michael;
HENKEL Bernd;
STENGELIN Siegfried;
EVERS Andreas;
LORENZ Martin;
LORENZ Katrin.

(73) SANOFI (FR)

(74) Cabinet CAZENAVE SARL, B.P. 500,
YAOUNDE (CM).

(57) The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

[Consulter le mémoire](#)**(11) 17437**

(51) F41H 5/04 (06.01)

(21) 1201500248 - PCT/IT12/000385

(22) 18.12.2012


(54) Protective device.

(72) CIOFFI Cosimo.

(73) B-MAX S.r.l. (IT)

(74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, Blvd. du 20 Mai, Immeuble Centre Commercial de l'Hôtel Hilton, 2è Etage, Porte 208A, P.O. Box 8211, YAOUNDE (CM).

(57) Described is a protecting device comprising a first internal resistant layer (2) made from a steel having a failure load equal to or greater than 30,000 kg/cm² and perfectly elastic between 0 and at least 10,000 kg/cm², and at least one second layer (3) made from polymeric material.



[Consulter le mémoire](#)

(11) **17438**

(51) E04C 3/08 (06.01)

(21) 1201500252 - PCT/US13/076399

(22) 19.12.2013

(30) US n° 61/739,217 du 19/12/2012
US n° 14/133,151 du 18/12/2013

(54) Truss configuration.

(72) VANKER, John Louis;
LASTOWSKI, Michael J.

(73) PATCO (US)

(74) SCP AKKUM, AKKUM & Associates,
Quartier Mballa II, Dragages, B.P. 4966,
YAOUNDE (CM).

(57) An implementation of a truss configuration disclosed herein includes a plurality of trusses, each including a top chord, a bottom chord, a plurality of exterior braces, and a plurality of interior braces, wherein length of each of the plurality of exterior braces is substantially similar and wherein the angle between each of the exterior braces and the top chord is substantially similar. Furthermore, length of each of the plurality of interior braces is substantially similar and wherein the angle between each of the alternate interior braces and the top chord is substantially similar.




Fig. 1

[Consulter le mémoire](#)

(11) **17439**

(51) F01D 15/10 (06.01)

(21) 1201500254 - PCT/EP13/077261

(22) 18.12.2013

(30) IT n° FI2012A000292 du 24/12/2012


(54) Gas turbines in mechanical drive applications and operating methods.

(72) SANTINI, Marco.

(73) NUOVO PIGNONE SRL (IT)

(74) SCP AKKUM, AKKUM & Associates,
Quartier Mballa II, Dragages, B.P. 4966,
YAOUNDE (CM).

(57) A drive system for driving a load (21) by means of a gas turbine (3). The gas turbine comprises a gas generator (5) having a gas-generator rotor (5R) and comprising at least one gas-generator compressor (9) and one high-pressure turbine (11) driving the gas-generator compressor. The gas turbine further comprises a power turbine (7) having a power-turbine rotor (7R), which is torsionally independent of the gas-generator rotor (5R). The load is connected to the power-turbine rotor (7R). The system further comprises an electric motor/generator (23) mechanically connected to the gas-generator rotor (5R) and electrically connected to an electric power grid (G). The electric motor/generator (23) is adapted to function alternatively : as a generator for converting mechanical power from the gas turbine (3) into electrical power; and as a motor for supplementing driving power to the load (21).



[Consulter le mémoire](#)

(11) **17440**

(51) A61P 37/00; C07K 16/28; A61K 39/395

(21) 1201500261 - PCT/EP13/077898

(22) 23.12.2013

(30) US n° 61/748,201 du 02/01/2013

(54) Antibodies that bind to TL1a and their uses.

(72) ATTINGER, Antoine;

BACK, Jonathan Albert;

BLEIN, Stanislas;

LISSILAA, Rami;

SKEGRO, Darko.

(73) Glenmark Pharmaceuticals S.A. (CH)

(74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, Blvd. du 20 Mai, Immeuble Centre Commercial de l'Hôtel Hilton, 2è Etage, Porte 208A, P.O. Box 8211, YAOUNDE (CM).

(57) The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, 5 and-or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.




Fig. 4

[Consulter le mémoire](#)

(11) **17441**

(51) A61K 31/4355; A61P 25/00; A61K 31/436 C07D 213/26; A61K 31/44

(21) 1201500267 - PCT/EP12/063219

(22) 06.07.2012

(30) DK n° PA 2011 00520 du 08/07/2011

(54) Positive allosteric modulators of nicotinic acetylcholine receptor.

(72) ESKILDSEN, Jørgen;


SAMS, Anette Graven;

PÜSCHL, Ask.

(73) H Lundbeck A/S (DK)

(74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, Blvd. du 20 Mai, Immeuble Centre Commercial de l'Hôtel Hilton, 2è Etage, Porte 208A, P.O. Box 8211, YAOUNDE (CM).

(57) The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine $\alpha 7$ (symbole alpha) receptor.



[Consulter le mémoire](#)

(11) **17442**

(51) C09K 8/40; E21B 43/22

(21) 1201500282 - PCT/US14/011802

(22) 16.01.2014

(30) US n° 13/786,227 du 05/03/2013

(54) Alkyl polyglycoside derivative as biodegradable spacer surfactant.

(72) MUTHUSAMY, Ramesh;
DESHPANDE, Abhimanyu Pramod;
PATIL, Rahul Chandrakant;
PATIL, Sandip Prbhakar.

(73) HALLIBURTON ENERGY SERVICES, INC. (US)

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) A spacer fluid comprising : (a) water; and (b) an alkyl polyglycoside derivative, wherein the alkyl polyglycoside derivative is selected from the group consisting of sorbitan fatty acids; functionalized sulfonates, functionalized betaines, an inorganic salt of any of the foregoing, and any combination of any of the foregoing. Preferably, the spacer fluid additionally comprises a solid particulate, such as a weighting agent. A method of displacing an oil-based drilling mud from a portion of a well comprising the steps of : (A) forming the spacer fluid; and (B) introducing the spacer fluid into the well.




Fig. 1

[Consulter le mémoire](#)

(11) **17443**

(51) C09K 8/42; C09K 8/467

(21) 1201500283 - PCT/US13/077447

(22) 23.12.2013

(30) US n° 13/786,113 du 05/03/2013

(54) Alkyl polyglycoside derivative as biodegradable foaming surfactant for cement.

(72) MUTHUSAMY, Ramesh;
DESHPANDE, Abhimanyu Pramod;
PATIL, Rahul Chandrakant;
LEWIS, Samuel J.

(73) HALLIBURTON ENERGY SERVICES, INC. (US)

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) A cement composition : (a) a hydraulic cement; (b) water; and (c) an alkyl polyglycoside derivative, wherein the alkyl polyglycoside derivative is selected from the group consisting of : sulfonates, betaines, an inorganic salt of any of the foregoing, and any combination of any of the foregoing. A method comprising the steps of : (A) forming the cement composition; and (B) introducing the cement composition into the well. Preferably, the cement composition is foamed.

[Consulter le mémoire](#)

(11) **17444**

(51) A61K 39/015

(21) 1201500287 - PCT/EP14/051149

(22) 21.01.2014

(30) FR n° 1350508 du 21/01/2013

(54) Vaccins contre le paludisme gestationnel.

(72) TUIKUE NDAM, Nicaise;
DELORON, Philippe;
DORITCHAMOU, Justin.

(73) INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD) (FR)

(74) Cabinet ISIS CONSEILS (SCP), B.P. 15067, YAOUNDE (CM).

(57) The present invention relates to combinations of polypeptides or of polynucleotides corresponding to a specific region of the part N-terminal portion of the VAR2CSA protein of different parasitic families or lines of Plasmodium falciparum and their use in the

prevention of pregnancy-associated malaria. The invention also relates to immunogenic compositions and to vaccines useful for preventing malaria in pregnant women.




Fig. 3

[Consulter le mémoire](#)

(11) **17445**

(51) C07D 403/12; A61P 11/06

C07D 487/04; A61P 19/02

(21) 1201500290 - PCT/EP14/052217

(22) 05.02.2014

(30) EP n° 13154256.5 du 06/02/2013

(54) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity.

(72) GNAMM Christian;

OOST Thorsten;

PETERS Stefan;


HOESCH Holger;

RIES Uwe Jörg.

(73) Boehringer Ingelheim International GmbH (DE)

(74) Cabinet ÉKÉMÉ LYSAGHT SARL, B.P. 6370, YAOUNDE (CM).

(57) This invention relates to substituted bicyclic dihydropyrimidinones of formula (I) and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.



Formula I

[Consulter le mémoire](#)

(11) **17446**

(51) C25C 7/02; C25C 5/00; C25C 1/12

(21) 1201500291 - PCT/AU13/001109

(22) 26.09.2013

(30) AU n° 2012904201 du 26/09/2012

(54) A cathode and method of manufacturing.


(72) CEREZO, Jason Robert.

(73) STEELMORE HOLDINGS PTY LTD (AU);
GLENCORE TECHNOLOGY PTY LTD (AU).

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) An electrode for electrolytic processes, the electrode comprising a conducting bar and a plate attached to the conducting bar, wherein the conducting bar has a conducting member

attached thereto to increase the conductivity of the conducting bar.



[Consulter le mémoire](#)

(11) **17447**

(51) C09K 8/50; C09K 8/528; C09K 8/506

(21) 1201500292 - PCT/US14/039083

(22) 22.05.2014

(30) US n° 61/828,331 du 29/05/2013

(54) Use of organic acids or a salt thereof in surfactant-based enhanced oil recovery formulations and techniques.

(72) SOLASTIOUK, Pierre;

SALAZAR, Luis;

LEWIS, David, C.

(73) HUNTSMAN PETROCHEMICAL LLC (US)

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) The present disclosure provides a surfactant formulation for use in treating and recovering fossil fluid from a subterranean formation. The surfactant formulation includes a nonionic surfactant, organic acid selected from citric acid, diglycolic acid, glycolic acid and a salt thereof and injection water. The surfactant formulation may be injected into one or more injection wells located within the subterranean formation and fossil fluids can then be subsequently recovered from one or more producing wells.

[Consulter le mémoire](#)

(11) **17448**

(51) A61K 31/137; A61K 9/08; A61P 47/00 A61P 31/10

(21) 1201500296 - PCT/EP14/051288

(22) 23.01.2014

(30) US n° 61/761953 du 07/02/2013

US n° 61/781560 du 14/03/2013

(54) Topical antifungal composition for treating onychomycosis.

(72) MAILLAND Federico;

LEGORA Michela;

CERIANI Daniela;

IOB Giuliana.

(73) Polichem S.A. (LU)

(74) Cabinet ÉKÉMÉ LYSAGHT SARL, B.P. 6370, YAOUNDE (CM).

(57) The present invention is directed to a nail lacquer consisting essentially of terbinafine as an antimycotic agent, hydroxypropyl chitosan as film forming agent, water and a lower alkanol as solvents. The invention is also directed to a method for treating onychomycosis by topically administering such a nail lacquer to a patient in need of such a treatment.



Fig. 2

[Consulter le mémoire](#)

(11) **17449**

(51) C07D 213/75; C07D 401/12; A61K 31/44 A61P 29/00

(21) 1201500299 - PCT/US14/013652

(22) 29.01.2014

(30) US n° 61/759,059 du 31/01/2013


(54) Pyridone amides as modulators of sodium channels.

(72) HADIDA-RUAH, Sara, Sabina;
ANDERSON, Corey;
ARUMUGAM, Vijayalaxmi;
ASGIAN, Iuliana, Luci;
BEAR, Brian, Richard;
TERMIN, Andreas, P.;
JOHNSON, James, Philip.


(73) Vertex Pharmaceuticals Incorporated (US)

(74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, Blvd. du 20 Mai, Immeuble Centre Commercial de l'Hôtel Hilton, 2è Etage, Porte 208A, P.O. Box 8211, YAOUNDE (CM).

(57) The invention relates to pyridine amide compounds of formula I and I' or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels : formula I and I'. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.



I



I'.

[Consulter le mémoire](#)

(11) **17450**

(51) A61K 9/16; A61K 9/20; A61K 31/501
A61K 31/513

(21) 1201500300 - PCT/US14/013953

(22) 30.01.2014

(30) US n° 61/759,320 du 31/01/2013
US n° 61/772,292 du 04/03/2013
US n° 61/828,899 du 30/05/2013
US n° 61/870,729 du 27/08/2013
US n° 61/897/793 du 30/10/2013
US n° 61/907,332 du 21/11/2013



(54) Combination formulation of two antiviral compounds.

(72) CHAL Ben;
MOGALIAN Erik;
PAKDAMAN Rowchanak;
OLIYAI Reza;
STEFANIDIS Dimitrios;
ZIA Vahid.

(73) GILEAD PHARMASSET LLC. (US)

(74) GAD CONSULTANTS SCP, B.P. 13448, YAOUNDE (CM).

(57) Disclosed are pharmaceutical compositions having an effective amount of substantially amorphous ledipasvir and an effective amount of substantially crystalline sofosbuvir.



[Consulter le mémoire](#)

(11) **17451**

(51) C22B 3/28; C22B 59/00
(21) 1201500301 - PCT/EP14/051822
(22) 30.01.2014

(30) FR n° 1350784 du 30/01/2013

(54) Procédé d'extraction sélective du scandium.

(72) VINCEC Maxime.

(73) ERAMET (FR)

(74) Cabinet CAZENAVE SARL, B.P. 500, YAOUNDE (CM).

(57) La présente invention concerne un procédé de dés extraction sélective du scandium vis-à-vis du thorium et/ou du zirconium et/ou du titane dissous dans une solution organique à base d'une aminé primaire d'alkyle caractérisé en ce qu'il comprend les étapes successives suivantes : - a) mise en contact d'une solution organique à base d'une aminé primaire d'alkyle dans laquelle sont dissous du scandium et un métal choisi parmi le thorium, le zirconium, le titane et leurs mélanges avec une solution aqueuse acide de sels de phosphate de façon à former un complexe entre le scandium et les phosphates, - b) séparation de la solution aqueuse comprenant le complexe entre le scandium et les phosphates, de la solution organique à base d'une aminé primaire d'alkyle, - c) récupération de la solution aqueuse comprenant le complexe entre le scandium et les phosphates. Il concerne en outre un procédé d'extraction sélective du scandium d'une solution aqueuse acide de sulfate contenant du scandium et un métal choisi parmi le thorium, le zirconium, le titane et leurs mélanges et un procédé d'extraction sélective du scandium, du thorium, du zirconium et éventuellement du titane d'une solution aqueuse acide de sulfate contenant du scandium, du thorium, du zirconium et éventuellement du titane à l'aide d'une solution organique à base d'une aminé primaire d'alkyle utilisant ce procédé de dés extraction.




FIG.1

[Consulter le mémoire](#)

(11) **17452**

(51) C07F 5/02; A61K 31/09; A61P 33/02

(21) 1201500303 - PCT/US14/014266

(22) 31.01.2014

(30) US n° 61/759,981 du 01/02/2013

(54) Boron-containing small molecules as antiprotozoal agents.

(72) AKAMA, Tsutomu;

EASOM, Eric;

FREUND, Yvonne;

PLATTNER, Jacob, J.;

SLIGAR, Jessica;

CHEN, Daitao;


FREEMAN, Jennifer;

PERALES, Joe.

(73) ANACOR PHARMACEUTICALS, INC. (US)

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.



Compound #	T.brucei IC50 (mg/mL)	T.cruzi IC50 (mg/mL)	T.congo IC50 (mg/mL)	L. donovani axenic IC50 (ug/mL)	L. donovani macrophage IC50 (ug/mL)	L929 IC50 (ug/mL)
1	0.037	0.214	0.04			
2	0.01	0.012				
3	0.035	0.047	0.0952			
4	0.045	0.07	0.116			
5						
6	0.019	0.108	0.045			
7	0.023	0.052				
8	0.04	0.013	0.0724			
9	0.118		0.118			
10	0.136		0.136			
11	0.085					
12	0.142					
13	0.097	1.28	0.199			
14	0.29	0.947	0.671			
15	0.126	0.263	0.303			
16	0.276	0.86	0.276			
17	0.086	0.313	0.217			
18	0.077	0.216	0.185			
19	0.175	0.283	0.459			
20	0.401	2.55	0.401			
21	0.875					

FIG. 1A

Compound #	T.brucei IC50 (mg/mL)	T.cruzi IC50 (mg/mL)	T.congo IC50 (mg/mL)	L. donovani axenic IC50 (ug/mL)	L. donovani macrophage IC50 (ug/mL)	L929 IC50 (ug/mL)
22	0.168					
23						
24	0.169	0.39	0.454			
25	0.075	0.13	0.188			
26	0.578	0.148	1.35			
27	0.177	1.77	0.393			
28	0.073	0.38	0.058			
29	0.159	0.068	0.366			
30	0.214	0.719	0.214			
31	0.133	0.301	0.133			
32	0.171	1.19	0.386			
33	0.0369	0.0818	0.0537	0.14		8.03
34	0.011	0.129	0.019	0.1	2.39	1.27
35	0.0275	0.07	0.0655	0.27		5.17
36	0.03	0.123	0.0746	0.2		4
37	0.0101	0.112	0.226	0.72		10
38	0.038	0.341	0.091			
39	0.0296	0.0879	0.014	0.05	0.33	10
40	0.0639	0.432	0.0878	0.23		9.05

FIG. 1B

FIG. 2

Compound #	Dose (mg/kg, IP)	Days	Survived/infected at Day 60
1	10	4	5/5
1	10	1	5/5
1	3	4	5/5
1	1	4	0/5
28	10	4	4/5
28	3	4	0/5
34	10	4	5/5
34	3	4	3/5
39	10	4	5/5
39	3	4	0/5

(11) 17453

(51) C22B 60/02

(21) 1201500307 - PCT/US14/013106

(22) 27.01.2014

(30) US n° 61/767,286 du 21/02/2013

(54) Continuous ion exchange process integrated with membrane separation for recovering uranium.

(72) REZKALLAH, Areski;

AERTS, Peter E.M.;

KRUEGER, Robert T.

(73) Rohm and Haas Company (US);

Dow Global Technologies LLC (US)

(74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, Blvd. du 20 Mai, Immeuble Centre Commercial de l'Hôtel Hilton, 2è Etage, Porte 208A, B.P. 8211, YAOUNDE (CM).

(57) A continuous ion exchange system and method for recovering uranium from a pregnant liquor solution wherein the method includes the steps of : (a) treating the pregnant liquor solution (16) with a membrane (28) to produce : i) a leach permeate solution (30) at least partially depleted of uranium and carbonate and ii) a leach concentrate solution (30') having a relatively higher concentration of uranium and carbonate and which is at least partially depleted of chloride; (b) passing the leach concentrate stream (30') through an ion exchange bed to load uranium onto a strong base anion exchange resin and produce an untreated barren (18) solution depleted of uranium, (c) passing an eluant solution (20) comprising bicarbonate through the loaded ion exchange bed to strip uranium from the strong base anion exchange resin and produce an eluate (22) comprising uranium and bicarbonate, (d) precipitating uranium (24) from the eluate (22) to produce a residual eluant solution (26) depleted of uranium, and (e) repeating steps (a)-(d).




Fig. 1

[Consulter le mémoire](#)


(11) **17454**

- (51) C07D 295/096
 (21) 1201500309 - PCT/EP14/053313
 (22) 20.02.2014
 (30) DK n° PA201300104 du 22/02/2013
 (54) Vortioxetine manufacturing process.
 (72) RUHLAND, Thomas;
 CHRISTENSEN, Kim Lasse.

(73) H. Lundbeck A/S (DK)

(74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, Blvd. du 20 Mai, Immeuble Centre Commercial de l'Hôtel Hilton, 2è Etage, Porte 208A, P.O. Box 8211, YAOUNDE (CM).

(57) A process for the manufacture of vortioxetine is provided in which a compound of formula I is reacted with optionally substituted piperazine and 2,4-dimethylthiophenol(ate) followed by de-complexation.



Formula I

[Consulter le mémoire](#)

(11) **17455**

- (51) C05G 3/00; C05D 9/02
 (21) 1201500312 - PCT/GB14/050494
 (22) 20.02.2014
 (30) GB n° 1302997.0 du 20/02/2013
 (54) Fertiliser coating containing micronutrients.
 (72) WARD Stuart Charles;
 BUTLER Victoria Anne;
 OBRESTAD Torstein;
 TANDE Terje.

(73) Yara UK Limited (GB)

(74) Cabinet ÉKÉMÉ LYSAGHT SARL, B.P. 6370, YAOUNDE (CM).

(57) A single-step method for preparing a free-flowing, non-dusting micronutrient-coated particulate solid fertiliser material, the method comprising applying a single fluid onto particulate solid fertiliser material at ambient temperature without chemical reaction or chelation, said single fluid comprising a suspension of one or more micronutrient materials in an oil.

[Consulter le mémoire](#)


(11) **17456**

- (51) A61K 31/135; A61K 31/192
 (21) 1201500313 - PCT/EP14/052342
 (22) 06.02.2014
 (30) IT n° MI2013A000210 du 14/02/2013
 (54) Pharmaceutical compositions containing dexketoprofen and tramadol.
 (72) SCHMITZ, Reinhard;
 KOHL, Tobias.
 (73) Laboratorios Menarini SA (ES)
 (74) Cabinet Spoor & Fisher Inc. Ngwafor & Partners, Blvd. du 20 Mai, Immeuble Centre Commercial de l'Hôtel Hilton, 2è Etage, Porte 208A, P.O. Box 8211, YAOUNDE (CM).

(57) A pharmaceutical composition as a solid oral dosage form is described, comprising : i) a combination of two pharmacological active principles, dexketoprofen salt with an organic or inorganic base and tramadol salt with an organic or inorganic acid, wherein : the organic or inorganic base is selected in the group : trometamol, trimethylamine, dimethylamine, ethylamine, triethylamine, diethylamine, L-lysine, L-arginine, diethanolamine, sodium hydroxide, calcium hydroxide the organic or inorganic acid is selected in the group : hydrochloric, hydrobromic, phosphoric, sulfuric, methanesulfonic, benzenesulfonic, toluenesulfonic, acetic, propionic, malic, maleic, succinic, citric, L-tartaric, lactic, malonic, aspartic, glutamic; ii) microcrystalline cellulose as a filler; iii) a binder selected in the group : maize starch, pre-gelatinised maize starch, hypromellose or their

mixtures; iv) pharmaceutically acceptable excipients.

Figure 1



[Consulter le mémoire](#)

(11) **17457**

(51) C07D 471/08; A61P 15/00; A61P 11/00
A61P 35/00; A61P 27/00; A61P 17/00
A61K 31/439

(21) 1201500318 - PCT/EP14/054794

(22) 12.03.2014

(30) EP n° 13159240.4 du 14/03/2013

EP n° 13170005.6 du 31/05/2013


(54) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C.

(72) ANDERSKEWITZ Ralf;
GRAUERT Matthias;
GRÜNDL Marc;
HAEBEL Peter Wilhelm;
OOST Thorsten;
PAUTSCH Alexander;
PETERS Stefan;
BINDER Florian;
VINTONYAK Viktor.

(73) Boehringer Ingelheim International GmbH
(DE)

(74) Cabinet ÉKÉMÉ LYSAGHT SARL,
B.P. 6370, YAOUNDE (CM).

(57) This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.



Formula I

[Consulter le mémoire](#)

(11) **17458**

(51) C07D 471/04; A61P 25/22; A61P 25/16
A61P 25/8; A61K 31/437; A61K 31/444
A61P 25/22; A61P 25/24; A61P 25/28
A61P 37/08

(21) 1201500323 - PCT/IB14/058840

(22) 06.02.2014

(30) US n° 61/766,268 du 19/02/2013

(54) Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of CNS and other disorders.


(72) CHAPPIE, Thomas Allen;
HAYWARD, Matthew Merrill;
PATEL, Nandini Chaturbhai;
VERHOEST, Patrick Robert.

(73) PFIZER INC. (US)

(74) SCP AKKUM, AKKUM & Associates,
Quartier Mballa II, Dragages, B.P. 4966,
YAOUNDE (CM).

(57) The present invention is directed to compounds of formula (I) : or a pharmaceutically acceptable salt thereof, wherein the substituents

are as defined herein. The compounds of formula (I) are useful as inhibitors of PDE4 for the treatment of CNS and other disorders.



Formula I

[Consulter le mémoire](#)

(11) **17459**

(51) A61K 31/00; A61K 31/40; A61P 1/16

(21) 1201500324 - PCT/IN13/000391

(22) 25.06.2013

(30) IN n° 1468/MUM/2013 du 22/04/2013

(54) A novel composition for nonalcoholic fatty liver disease (NAFLD).

(72) PATEL Pankaj;

HARIPRASAD JANI Rajendrakumar.

(73) Cadila Healthcare Limited (IN)

(74) Cabinet ÉKÉMÉ LYSAGHT SARL, B.P. 6370, YAOUNDE (CM).

(57) The present invention provides a compound of formula (I) or pharmaceutically acceptable thereof, wherein 'R' is herein described. In addition, the invention relates to a composition comprising an effective therapeutic amount of a compound of formula (I) and methods of using the compounds for treating or preventing a disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).




Figure 2

[Consulter le mémoire](#)

(11) **17460**

(51) C07D 487/04; C07D 519/00

A61K 31/519; A61P 37/00

(21) 1201500328 - PCT/IB14/058889

(22) 11.02.2014

(30) US n° 61/767, 947 du 22/02/2013

(54) Pyrrolo [2, 3 - D]pyrimidine derivatives as inhibitors of Janus-Related Kinases (JAK).

(72) BROWN, Matthew Frank;

FENWICK, Ashley Edward;

FLANAGAN, Mark Edward;

GONZALES, Andrea;

JOHNSON, Timothy Allan;

KAILA, Neelu;

MITTON-FRY, Mark J.;

STROHBACH, Joseph Walter;

TENBRINK, Ruth E.;

TRZUPEK, John David;

UNWALLA, Rayomand Jal;

VAZQUEZ, Michael L.;

MIHIR, D. Parikh.

(73) PFIZER INC. (US)

(74) SCP AKKUM, AKKUM & Associates, Quartier Mballa II, Dragages, B.P. 4966, YAOUNDE (CM).

(57) Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, and pharmaceutical compositions containing them.

[Consulter le mémoire](#)

(11) **17461**

(51) A25L 1/40; A23L 1/228; A23L 1/304
A23L 1/03

(21) 1201500334 - PCT/EP14/053526

(22) 24.02.2014

(30) EP n° 13157731.4 du 05/03/2013

(54) Fortified savoury food concentrate.

(72) JANSEN, Franciscus, Johannes,
Henricus, Maria;

VELIKOV, Krassimir, Petkov;

DUCHATEAU, Gustaaf, Servaas, Marie,
Joseph, Emile;

VAN DER BURG-KOOREVAAR,
Monique, Cecilia, Désiré.

(73) Unilever N.V. (NL)

(74) Cabinet Spoor & Fisher Inc. Ngwafor &
Partners, Blvd. du 20 Mai, Immeuble Centre
Commercial de l'Hôtel Hilton, 2è Etage, Porte
208A, P.O. Box 8211, YAOUNDE (CM).

(57) The present invention relates to a savoury food concentrate comprising iron salt and a process to produce the same. It is therefore an aim of the present invention to provide a glutamate containing savoury food concentrate which comprises an iron salt, wherein the amount of off-color which appears upon storage of the food concentrate is reduced, preferably wherein off-coloring is absent. It is therefore a further object of the present invention to improve the bioavailability of iron in food concentrates. It was found that a composition comprising an iron salt and a further non-iron phosphate salt, provides reduced discolouration in food concentrate compositions comprising glutamate, and also provides improved bioavailability of the iron.

[Consulter le mémoire](#)

B
REPERTOIRE SUIVANT LA C.I.B.

(11)	(51)
17461	A25L 1/40
17459	A61K 31/00
17456	A61K 31/135
17448	A61K 31/137
17441	A61K 31/4355
17436	A61K 38/26 (06.01)
17444	A61K 39/015
17450	A61K 9/16
17422	A61P 31/00
17440	A61P 37/00
17430	B42D 15/10 (06.01)
17431	B62K 5/05 (06.01)
17432	B62K 5/08
17433	B62K 5/08 (06.01)
17434	B62K 5/10 (06.01)
17423	C02F 1/46 (06.01)
17455	C05G 3/00
17449	C07D 213/75
17454	C07D 295/096
17445	C07D 403/12
17458	C07D 471/04
17457	C07D 471/08
17460	C07D 487/04
17452	C07F 5/02
17442	C09K 8/40
17443	C09K 8/42
17447	C09K 8/50
17451	C22B 3/28
17453	C22B 60/02
17446	C25C 7/02
17427	E02F 7/00 (06.01)
17438	E04C 3/08 (06.01)

(11)	(51)
17429	E21B 7/08 (06.01)
17439	F01D 15/10 (06.01)
17435	F16L 15/00 (06.01)
17437	F41H 5/04 (06.01)
17428	G01C 11/06 (06.01)
17425	H02H 9/02 (06.01)
17424	H04B 1/00 (06.01)
17426	H04W 48/08 (06.01)

C
REPERTOIRE DES NOMS

AANENSEN, Ove T. and VALAND, Dag Arild (11) 17423 (51) C02F 1/46 (06.01)
ANACOR PHARMACEUTICALS, INC. (11) 17452 (51) C07F 5/02
Bemax Resources Limited (11) 17427 (51) E02F 7/00 (06.01)
B-MAX S.r.l. (11) 17437 (51) F41H 5/04 (06.01)
Boehringer Ingelheim International GmbH (11) 17445 (51) C07D 403/12 (11) 17457 (51) C07D 471/08
BP CORPORATION NORTH AMERICA, INC. (11) 17428 (51) G01C 11/06 (06.01)
Cadila Healthcare Limited (11) 17459 (51) A61K 31/00
ERAMET (11) 17451 (51) C22B 3/28
GILEAD PHARMASSET LLC. (11) 17450 (51) A61K 9/16
Glenmark Pharmaceuticals S.A. (11) 17440 (51) A61P 37/00
H. Lundbeck A/S (11) 17454 (51) C07D 295/096
H Lundbeck A/S (11) 17441 (51) A61K 31/4355
HALLIBURTON ENERGY SERVICES, INC. (11) 17442 (51) C09K 8/40 (11) 17443 (51) C09K 8/42
HUNTSMAN PETROCHEMICAL LLC (11) 17447 (51) C09K 8/50
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD) (11) 17444 (51) A61K 39/015
INSTITUT DE RECHERCHES MEDICALES ET D'ETUDES DES PLANTES MEDICINALES (IMPM) (11) 17422 (51) A61P 31/00
Laboratorios Menarini SA (11) 17456 (51) A61K 31/135

Mekimah, Djamel (11) 17425 (51) H02H 9/02 (06.01)
Morpho B.V. (11) 17430 (51) B42D 15/10 (06.01)
NUOVO PIGNONE SRL (11) 17439 (51) F01D 15/10 (06.01)
PATCO, LLC (11) 17438 (51) E04C 3/08 (06.01)
PFIZER INC. (11) 17458 (51) C07D 471/04 (11) 17460 (51) C07D 487/04
Polichem S.A. (11) 17448 (51) A61K 31/137
PRAD Research and Development Limited (11) 17429 (51) E21B 7/08 (06.01)
QUALCOMM INCORPORATED (11) 17424 (51) H04B 1/00 (06.01) (11) 17426 (51) H04W 48/08 (06.01)
Rohm and Haas Company and Dow Global Technologies LLC (11) 17453 (51) C22B 60/02
SANOFI (11) 17436 (51) A61K 38/26 (06.01)
STEELMORE HOLDINGS PTY LTD and GLENCORE TECHNOLOGY PTY LTD (11) 17446 (51) C25C 7/02
Unilever N.V. (11) 17461 (51) A25L 1/40
VALLOUREC OIL AND GAS FRANCE and NIPPON STEEL & SUMITOMO METAL CORPORATION (11) 17435 (51) F16L 15/00 (06.01)
Vertex Pharmaceuticals Incorporated (11) 17449 (51) C07D 213/75
YAMAHA HATSUDOKI KABUSHIKI KAISHA (11) 17431 (51) B62K 5/05 (06.01) (11) 17432 (51) B62K 5/08 (11) 17433 (51) B62K 5/08 (06.01) (11) 17434 (51) B62K 5/10 (06.01)
Yara UK Limited (11) 17455 (51) C05G 3/00